Literature DB >> 9697738

Early emergence of ganciclovir-resistant human cytomegalovirus strains in children with primary combined immunodeficiency.

D G Wolf1, I Yaniv, A Honigman, I Kassis, T Schonfeld, S Ashkenazi.   

Abstract

Children with primary combined immunodeficiency (CID) and human cytomegalovirus (HCMV) infection often deteriorate despite antiviral therapy. In this study, the emergence of ganciclovir-resistant strains was examined in 6 children with CID and HCMV infection, using sequence analysis of the HCMV UL97 gene and virus susceptibility assays. Mutations in the proposed ATP binding site associated with ganciclovir resistance were found in 4 of the 6 children. In 1 patient with B severe CID, an unusual multiplicity of mutations was found in the UL97 substrate binding domain between aa 590-606. All mutations were detected within 10 days to 3 weeks from initiation of therapy. The emergence of resistant strains in children with CID appears earlier than in other groups of HCMV-infected patients. These findings may have relevance to the cellular pathways involved in viral DNA repair and mutagenesis, and they indicate the need for early and frequent genotypic monitoring and prompt therapeutic modification in this patient population.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9697738     DOI: 10.1086/517468

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Emergence of multiple human cytomegalovirus ganciclovir-resistant mutants with deletions and substitutions within the UL97 gene in a patient with severe combined immunodeficiency.

Authors:  D G Wolf; I Yaniv; S Ashkenazi; A Honigman
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 2.  Human cytomegalovirus resistance to antiviral drugs.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  Thymic tolerance to only one viral protein reduces lymphocytic choriomeningitis virus-induced immunopathology and increases survival in perforin-deficient mice.

Authors:  M von Herrath; B Coon; D Homann; T Wolfe; L G Guidotti
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 4.  Resistance of human cytomegalovirus to antiviral drugs.

Authors:  A Erice
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

5.  How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients.

Authors:  Firas El Chaer; Dimpy P Shah; Roy F Chemaly
Journal:  Blood       Date:  2016-10-19       Impact factor: 22.113

6.  How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients.

Authors:  Kathryn L Springer; Sunwen Chou; Shaobing Li; Roger H Giller; Ralph Quinones; James E Shira; Adriana Weinberg
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

Review 7.  Antiviral drug resistance of human cytomegalovirus.

Authors:  Nell S Lurain; Sunwen Chou
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 8.  Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants.

Authors:  Ellen Meijer; Greet J Boland; Leo F Verdonck
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

9.  Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection.

Authors:  K Yeon Choi; B Sharon; H H Balfour; K Belani; T C Pozos; M R Schleiss
Journal:  J Clin Virol       Date:  2013-05-18       Impact factor: 3.168

10.  Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D.

Authors:  Jenna M Iwasenko; Gillian M Scott; William D Rawlinson; Anne Keogh; Daniel Mitchell; Sunwen Chou
Journal:  J Med Virol       Date:  2009-03       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.